Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
Completed
- Conditions
- Parkinson Disease
- Registration Number
- NCT00311532
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy.
The secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Male or female, age 18 and older with a diagnosis of Parkinson's Disease
- Receiving pergolide as second-line therapy as prescribed by Summary of Product Characteristics
- Willing to participate and sign a consent to release medical information
- Have had an echocardiogram within 3 months of initiation of pergolide therapy with no evidence of cardiac valvulopathy
Exclusion Criteria
- There are no exclusion criteria for this study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇮🇹Parma, Italy